Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners
Chiasma is also entitled to receive an additional $10 million in early 2022 subject to the achievement of a commercial milestone.
- Chiasma is also entitled to receive an additional $10 million in early 2022 subject to the achievement of a commercial milestone.
- Healthcare Royalty Partners is a top-tier investment firm that provides important validation for Chiasma as we near our PDUFA date and move towards our goal of bringing the first oral somatostatin analog to acromegaly patients, said Raj Kannan, Chief Executive Officer of Chiasma.
- We appreciate the extensive due diligence conducted by Healthcare Royalty Partners and plan to use the proceeds from this non-dilutive financing to support our ongoing activities as we prepare for a robust U.S. commercial launch of MYCAPSSA, if approved.
- HealthCare Royalty Partners(HCR") is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.